|
JP2699794B2
(en)
*
|
1992-03-12 |
1998-01-19 |
三菱化学株式会社 |
Thieno [3,2-b] pyridine derivative
|
|
GB9214184D0
(en)
*
|
1992-07-03 |
1992-08-12 |
Smithkline Beecham Plc |
Pharmaceuticals
|
|
US5514690A
(en)
*
|
1992-11-17 |
1996-05-07 |
E. R. Squibb & Sons, Inc. |
Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
|
|
US5399562A
(en)
*
|
1994-02-04 |
1995-03-21 |
G. D. Searle & Co. |
Indolones useful as serotonergic agents
|
|
US5629429A
(en)
*
|
1995-06-07 |
1997-05-13 |
Bristol-Myers Squibb Company |
Process for preparing 4-arylamino-benzopyran and related compounds
|
|
US5612323A
(en)
*
|
1995-06-07 |
1997-03-18 |
Bristol-Myers Squibb Company |
Phosphinic ester substituted benzopyran derivatives
|
|
US5869478A
(en)
*
|
1995-06-07 |
1999-02-09 |
Bristol-Myers Squibb Company |
Sulfonamido substituted benzopyran derivatives
|
|
US5612370A
(en)
*
|
1995-06-07 |
1997-03-18 |
Bristol-Myers Squibb Company |
Phenylglycine and phenylalaninen amido benzopyran derivatives
|
|
EP1831225A2
(en)
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
GB2453058A
(en)
|
2006-04-04 |
2009-03-25 |
Univ California |
Kinase antagonists
|
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
SG187426A1
(en)
|
2008-01-04 |
2013-02-28 |
Intellikine Llc |
Certain chemical entities, compositions and methods
|
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
CN102124009B
(en)
|
2008-07-08 |
2014-07-23 |
因特利凯公司 |
Kinase inhibitors and methods of use
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
|
EP2358720B1
(en)
|
2008-10-16 |
2016-03-02 |
The Regents of The University of California |
Fused ring heteroaryl kinase inhibitors
|
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
|
WO2010129816A2
(en)
|
2009-05-07 |
2010-11-11 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
WO2011146882A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
JP2013545749A
(en)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
Heterocyclic compounds and uses thereof
|
|
PH12013501465A1
(en)
|
2011-01-10 |
2013-09-09 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
|
CA2828483A1
(en)
|
2011-02-23 |
2012-11-01 |
Intellikine, Llc |
Combination of kinase inhibitors and uses thereof
|
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
|
JP6027611B2
(en)
|
2011-07-19 |
2016-11-16 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
Heterocyclic compounds and uses thereof
|
|
TW201311663A
(en)
|
2011-08-29 |
2013-03-16 |
Infinity Pharmaceuticals Inc |
Heterocyclic compound and its use
|
|
JP6342805B2
(en)
|
2011-09-02 |
2018-06-13 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Substituted pyrazolo [3,4-D] pyrimidine and uses thereof
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
EP2900673A4
(en)
|
2012-09-26 |
2016-10-19 |
Univ California |
MODULATION OF IRE1
|
|
NZ708563A
(en)
|
2012-11-01 |
2019-02-22 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PT3052485T
(en)
|
2013-10-04 |
2021-10-22 |
Infinity Pharmaceuticals Inc |
HETEROCYCLIC COMPOUNDS AND THEIR USES
|
|
AU2015231413B2
(en)
|
2014-03-19 |
2020-04-23 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2016322552B2
(en)
|
2015-09-14 |
2021-03-25 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2017281797A1
(en)
|
2016-06-24 |
2019-01-24 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
EP3753924A1
(en)
*
|
2019-06-18 |
2020-12-23 |
AnaMar AB |
New tricyclic 5-ht2 antagonists
|